Chronic Kidney Disease (CKD) Malpractice

Chronic Kidney Disease (CKD) affects more than 37 million Americans, and it is one of the leading causes of morbidity and mortality worldwide. Despite its prevalence, CKD is frequently under-recognized in primary care. Too often, patients have obvious warning signs in their lab work—rising creatinine, abnormal estimated glomerular filtration rate (eGFR), or persistent protein in the urine—yet their doctors fail to diagnose, refer, or treat the condition in time.

When CKD progresses unchecked, patients face dialysis, transplant, and life-threatening complications. In these cases, failure to diagnose or treat isn’t just poor medicine—it can be medical malpractice.

On the Medicine: Understanding CKD

What Is Chronic Kidney Disease?

CKD is a progressive loss of kidney function over months or years. Healthy kidneys filter waste and excess fluid from the blood. In CKD, the kidneys gradually lose this ability, leading to buildup of toxins, electrolyte imbalances, anemia, bone disease, and eventually kidney failure.

The severity of CKD is staged based on eGFR (estimated glomerular filtration rate), a calculation derived from serum creatinine, age, sex, and race.

  • Stage 1: eGFR ≥90 with kidney damage (proteinuria, hematuria, structural abnormalities).
  • Stage 2: eGFR 60–89 with evidence of damage.
  • Stage 3a: eGFR 45–59.
  • Stage 3b: eGFR 30–44.
  • Stage 4: eGFR 15–29 (severe).
  • Stage 5: eGFR <15 (kidney failure, usually requiring dialysis or transplant).

Red Flag Labs That Should Trigger Action

Primary care doctors are often the first line of defense. Common labs that should never be ignored include:

  • Serum creatinine: Even a slight rise can indicate impaired filtration.
  • eGFR: Automatically reported with most chemistry panels; values <60 should trigger CKD evaluation.
  • Proteinuria / Albuminuria: The strongest predictor of CKD progression; often identified by a urine albumin-to-creatinine ratio (ACR).
  • Electrolyte abnormalities: Hyperkalemia, metabolic acidosis.
  • Anemia of CKD: Low hemoglobin in the setting of declining kidney function.

 

Despite clear guidelines, studies show that 40–60% of patients with CKD are never told they have it and are not referred to a nephrologist until very late.

How Common Is CKD and How Often Is It Missed?

  • Prevalence: CKD affects 15% of U.S. adults. Rates are higher in patients with diabetes and hypertension.

  • Missed diagnoses: One study found that nearly 40% of patients with stage 3 CKD had no documented diagnosis in their primary care chart.

  • Referral delays: Guidelines recommend nephrology referral at stage 4 CKD (eGFR <30), yet over 50% of patients reach kidney failure before ever seeing a nephrologist.

  • Outcomes: Early recognition slows progression. Use of ACE inhibitors or ARBs in proteinuric CKD reduces risk of kidney failure by 30–40%. Delayed recognition deprives patients of these interventions.

Why Missed CKD Is Malpractice

Failure to recognize and act on CKD is more than a clinical oversight. It can be malpractice when:

  • Abnormal labs are ignored. A PCP receives multiple chemistry panels showing eGFR in the 40s or 50s and rising creatinine, yet does not inform the patient or repeat testing.
  • Proteinuria is not worked up. Repeated abnormal urinalyses are disregarded instead of prompting quantification and treatment.
  • Referral is not made. Patient reaches stage 4 or 5 CKD without ever being sent to nephrology.
  • Failure to treat. No initiation of ACE inhibitors/ARBs, no adjustment of nephrotoxic medications, and no counseling on diet, blood pressure, or diabetes management.

 

These failures can accelerate progression to dialysis, shorten life expectancy, and deprive patients of transplant opportunities.

Why Early Detection of CKD Is Critical

Unlike many other conditions, chronic kidney disease is rarely reversible. Once a patient loses functioning nephrons (the tiny filters in the kidney), those filters are gone for good. The goal of treatment is not to cure CKD, but to halt or slow progression to kidney failure. That’s why early recognition is so important. If a primary care doctor ignores abnormal labs, the patient may lose years of opportunity for intervention that could have preserved kidney function.

What Early Intervention Can Do

Even simple, non-invasive measures—if implemented early—can drastically change the course of CKD:

  • Blood pressure control: Keeping blood pressure under 130/80 can cut the risk of CKD progression in half.
  • Blood sugar control in diabetics: Tight glycemic control reduces microvascular damage to the kidneys.
  • Medications: ACE inhibitors and ARBs reduce proteinuria and slow decline in kidney function by 30–40% in proteinuric CKD patients.
  • Lifestyle changes: A low-sodium diet, weight loss, exercise, smoking cessation, and reduced protein intake can ease the strain on kidneys and slow decline.
  • Avoiding nephrotoxic agents: Early education about avoiding NSAIDs, certain antibiotics, and unnecessary imaging contrast can prevent acute damage that accelerates CKD.

 

These interventions don’t reverse existing damage—but they preserve the function the patient still has.

The Tragedy of Missed Diagnosis

By contrast, when a PCP fails to recognize abnormal labs:

  • Patients often do not find out they have CKD until it is severe (Stage 4 or 5), when they are weeks or months from dialysis.
  • They miss years where simple steps could have preserved kidney function and delayed the need for dialysis by a decade or more.
  • They may suffer preventable complications: anemia, bone disease, metabolic acidosis, cardiovascular disease, and eventual kidney failure.
  • At that late stage, the only options are dialysis or transplant—treatments that are costly, invasive, and life-changing.

Why This Matters in Malpractice Cases

Legally, the issue is not that CKD is curable. It isn’t. The issue is that reasonable care requires catching it early enough to prevent further harm.

  • If abnormal creatinine and eGFR levels were ignored for years, a jury can see that as robbing the patient of the chance to slow progression.
  • Courts recognize that loss of a chance for a better outcome is actionable if the doctor’s negligence deprived the patient of that opportunity.
  • Defense attorneys often argue “CKD would have progressed anyway.” The counter is: maybe so, but not as quickly, not as severely, and not without the complications that could have been prevented.

 

In other words: early detection doesn’t cure CKD, but it buys time—often years or decades—before dialysis or transplant is needed. When doctors deny patients that chance, it is both a medical failure and a legal wrong.

California Law: The Legal Hurdles

In California, malpractice cases involving CKD face several challenges:

  • Known risk defenses: Defense experts often argue that CKD progression is inevitable in patients with diabetes or hypertension. The plaintiff must show that earlier recognition and treatment would have slowed or prevented progression.
  • CACI 505 (Success Not Required): Defense attorneys remind juries that doctors are not liable simply because treatment was unsuccessful. The key is proving that the PCP fell below the standard of care by ignoring abnormal labs or failing to act.
  • Causation battles: Experts are essential to show that earlier intervention (blood pressure control, nephrology referral, ACE inhibitor therapy) would more likely than not have altered the patient’s outcome.

 

Despite these hurdles, juries can and do hold doctors accountable when blatant red flags are ignored.

Other Malpractice Issues in CKD Cases

Beyond failure to diagnose, other common malpractice themes include:

  • Medication errors (e.g., prescribing NSAIDs or contrast dye to CKD patients without precautions).
  • Failure to adjust dosages of renally cleared drugs.
  • Failure to recognize acute kidney injury (AKI) superimposed on CKD, accelerating damage.
  • Failure to prepare patients for dialysis or transplant listing in time.

Statistics on CKD Outcomes

  • Patients with CKD have a 3.6-fold higher risk of cardiovascular death than the general population.
  • Progression to end-stage kidney disease (ESKD) requiring dialysis occurs in 1–2% of stage 3 patients per year, but rates are much higher if left untreated.
  • The annual cost of dialysis in the U.S. is over $90,000 per patient, borne by Medicare. Preventing progression through timely PCP intervention is both medically and economically critical.

Our Experience

We have seen multiple cases where patients had years of abnormal kidney labs, yet their doctors never told them they had CKD, never referred them to nephrology, and never started basic protective therapies. These omissions often make the difference between living independently and being tethered to dialysis for life.

While these cases are challenging under California law, they are worth pursuing when records show repeated missed opportunities to intervene.

Conclusion: Missed CKD Is Preventable—and Actionable

CKD does not appear overnight. It is almost always detectable years in advance through basic labs. When primary care doctors ignore those labs, fail to inform patients, and allow kidneys to silently deteriorate, they are not just negligent—they may be liable for malpractice.

If you or a loved one has suffered harm because your doctor failed to diagnose or act on chronic kidney disease, our firm can help. We know the medicine. We know the law. And we fight for patients who deserved better care, contact us today.

Contact Us

Get in touch today, and take the first step towards reclaiming your peace of mind.

    You agree to our friendly privacy policy.

    By providing your phone number, you agree to receive text messages from Ikuta Hemesath. Message and data rates may apply. Message frequency varies.